Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The presence of certain mutations in HCC, such as TERT and TP53, have a suspected or proven prognostic role in resected patients, but lack a morphological or immunophenotypic counterpart, which would allow us to define which tumours are rationally candidate for molecular biology analysis. The identification of a histological and immunohistochemical algorithm to determine which HCCs to take to NGS for prognostic purposes will save time and economic costs in the laboratory by rationalising available resources. In the future, the application of the immunohistochemical and molecular algorithm on biopsy could allow better prognosis and predictivity even before surgery/therapy.

Who May Be Eligible (Plain English)

Who May Qualify: - Age ≥18 years - Patients resected for HCC - Availability of NGS data - Availability of paraffin material for immunohistochemistry investigations Who Should NOT Join This Trial: - None Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age ≥18 years * Patients resected for HCC * Availability of NGS data * Availability of paraffin material for immunohistochemistry investigations Exclusion Criteria: * None

Treatments Being Tested

DIAGNOSTIC_TEST

Immunohistochemistry and in situ hybridisation analysis

immunohistochemistry and in situ hybridisation analysis for several markers, including p53, beta-Catenin and albumin, but also markers considered diagnostic for HCC such as Glutamin Synthetase, Glypican-3 and HSP70, to identify a more rational diagnostic-prognostic algorithm for primary liver lesions.

Locations (1)

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy